文献速递肿瘤 PET/CT甲状腺核医学

转移性乳腺癌患者[18F]FES与[18F]FDHT PET的视觉与定量评估:观察者间变异性研究

Visual and quantitative evaluation of [18F]FES and [18F]FDHT PET in patients with metastatic breast cancer: an interobserver variability study.
PubMed 文献 · EJNMMI Res · 2020-04-19

本前瞻性两中心研究纳入10例ER阳性转移性乳腺癌患者,共识别120个病灶,由两名独立观察者进行视觉与定量评估。结果显示[18F]FES PET视觉观察者间一致性高(阳性84%、阴性83%,kappa=0.67),定量ICC高(SUVmax 0.98);[18F]FDHT PET视觉一致性较低(阳性49%、阴性74%,kappa=0.23),但定量一致性良好(ICC 0.75-0.78)。

要点

  • [18F]FES PET视觉与定量评估观察者间一致性高,支持其临床应用。
  • [18F]FDHT PET视觉一致性较低(kappa=0.23),定量一致性良好。
  • [18F]FDHT PET定量分析在乳腺癌中具有重要性。

核心结论

  • [18F]FES PET的视觉和定量评估显示高观察者间一致性,结果支持其在临床实践中使用。
  • [18F]FDHT PET视觉一致性相对较低(因肿瘤-背景比值低),但定量一致性良好,强调定量分析在乳腺癌中的相关性。

研究设计与样本

  • 前瞻性两中心研究,纳入10例ER阳性转移性乳腺癌患者,共识别120个病灶。
  • 69个病灶经传统影像识别(骨扫描或高分辨率CT上>1 cm的病灶),51个病灶仅经[18F]FES和[18F]FDHT PET识别。
  • 所有病灶由两名独立观察者进行视觉和定量评分,视觉阳性定义为摄取高于背景,定量采用SUVmax、SUVpeak和SUVmean。

主要发现

  • [18F]FES PET视觉分析观察者间绝对阳性一致率为84%、阴性一致率为83%(kappa=0.67,95%CI 0.48-0.87)。
  • [18F]FDHT PET视觉分析观察者间绝对阳性一致率为49%、阴性一致率为74%(kappa=0.23,95%CI -0.04-0.49)。
  • [18F]FES PET定量ICC:SUVmax 0.98(95%CI 0.96-0.98)、SUVpeak 0.97(95%CI 0.96-0.98)、SUVmean 0.89(95%CI 0.83-0.92)。
  • [18F]FDHT PET定量ICC:SUVmax 0.78(95%CI 0.66-0.85)、SUVpeak 0.76(95%CI 0.63-0.84)、SUVmean 0.75(95%CI 0.62-0.84)。

关键数值与推荐

  • 视觉PET阳性病灶定义为摄取高于背景。
  • 定量分析采用SUVmax、SUVpeak和SUVmean。

临床怎么用

  • [18F]FES PET的视觉和定量评估一致性高,结果支持其在临床实践中使用。
  • [18F]FDHT PET视觉一致性较低,但定量一致性良好,强调定量分析在乳腺癌中的相关性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Correct identification of tumour receptor status is important for treatment decisions in breast cancer. [18F]FES PET and [18F]FDHT PET allow non-invasive assessment of the oestrogen (ER) and androgen receptor (AR) status of individual lesions within a patient. Despite standardised analysis techniques, interobserver variability can significantly affect the interpretation of PET results and thus clinical applicability. The purpose of this study was to determine visual and quantitative interobserver variability of [18F]FES PET and [18F]FDHT PET interpretation in patients with metastatic breast cancer. METHODS: In this prospective, two-centre study, patients with ER-positive metastatic breast cancer underwent both [18F]FES and [18F]FDHT PET/CT. In total, 120 lesions were identified in 10 patients with either conventional imaging (bone scan or lesions > 1 cm on high-resolution CT, n = 69) or only with [18F]FES and [18F]FDHT PET (n = 51). All lesions were scored visually and quantitatively by two independent observers. A visually PET-positive lesion was defined as uptake above background. For quantification, we used standardised uptake values (SUV): SUVmax, SUVpeak and SUVmean. RESULTS: Visual analysis showed an absolute positive and negative interobserver agreement for [18F]FES PET of 84% and 83%, respectively (kappa = 0.67, 95% CI 0.48-0.87), and 49% and 74% for [18F]FDHT PET, respectively (kappa = 0.23, 95% CI - 0.04-0.49). Intraclass correlation coefficients (ICC) for quantification of SUVmax, SUVpeak and SUVmean were 0.98 (95% CI 0.96-0.98), 0.97 (95% CI 0.96-0.98) and 0.89 (95% CI 0.83-0.92) for [18F]FES, and 0.78 (95% CI 0.66-0.85), 0.76 (95% CI 0.63-0.84) and 0.75 (95% CI 0.62-0.84) for [18F]FDHT, respectively. CONCLUSION: Visual and quantitative evaluation of [18F]FES PET showed high interobserver agreement. These results support the use of [18F]FES PET in clinical practice. In contrast, visual agreement for [18F]FDHT PET was relatively low due to low tumour-background ratios, but quantitative agreement was good. This underscores the relevance of quantitative analysis of [18F]FDHT PET in breast cancer. TRIAL REGISTRATION: ClinicalTrials.gov, NCT01988324. Registered 20 November 2013, https://clinicaltrials.gov/ct2/show/NCT01988324?term=FDHT+PET&draw=1&rank=2.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Mammatas LH, Venema CM, Schröder CP, et al. Visual and quantitative evaluation of [18F]FES and [18F]FDHT PET in patients with metastatic breast cancer: an interobserver variability study. EJNMMI Res. 2020. PMID: 32307594. doi:10.1186/s13550-020-00627-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。